Arabic Arabic English English French French German German
dark

Benefit unproven for self-administered high-flow therapy in COPD and type 1 respiratory failure

No benefit of high-flow therapy (HFT) can be derived from the available study data for patients with advanced chronic obstructive pulmonary disease (COPD) or chronic type 1 respiratory failure. It therefore remains unclear whether this form of treatment has advantages over long-term oxygen therapy (LTOT) or non-invasive ventilation (NIV). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Cycling linked to reduced all-cause, CVD mortality in diabetes

Next Post

Rates of adverse events lower with apixaban for A-fib in older adults

Related Posts
Total
0
Share